Metraipolis › archive › dc_d33d0cb875d3
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy — Europe PMC PMID:40974042
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40974042
- DOI
- 10.1002/cpt.70071
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T21:11:08.898Z
- SHA-256 of the archived text
e6a4f805a1d8bd20366f756624dc748ea6f08900fe33e5cc8634c9fcccd9dcde- Stable URL of this page
https://metraipolis.com/documento/dc_d33d0cb875d3
How to cite
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy — Europe PMC PMID:40974042 — Europe PMC (en), https://europepmc.org/article/MED/40974042 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d33d0cb875d3 (Metraipolis archive dc_d33d0cb875d3, sha256 e6a4f805a1d8bd20366f756624dc748ea6f08900fe33e5cc8634c9fcccd9dcde)
BibTeX
@misc{dcd33d0cb875d3,
title = {Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy — Europe PMC PMID:40974042},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40974042},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d33d0cb875d3; sha256 e6a4f805a1d8bd20366f756624dc748ea6f08900fe33e5cc8634c9fcccd9dcde},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40974042. Agents can read the archived copy with the MCP tool read_document.